BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC
Bio-Techne (NASDAQ: TECH) has won another legal case against Miltenyi Biotec in the Cologne Regional Court, Germany, regarding the unauthorized reverse engineering of Bio-Techne's proprietary NKG2C/CD159c antibodies. The court found that Miltenyi's antibodies had 100% identical variable regions to Bio-Techne's R&D Systems branded products.
This victory follows a similar 2023 case where Miltenyi was found to have reverse engineered Bio-Techne's TIGIT and CCR-7 antibodies. The court has awarded Bio-Techne monetary damages for sales of the reverse engineered antibodies, reimbursement of costs for demonstrating copying, and rights to additional information about Miltenyi's unlawful activities. Miltenyi retains the right to appeal the ruling.
Bio-Techne (NASDAQ: TECH) ha vinto un'altra causa legale contro Miltenyi Biotec presso il Tribunale Regionale di Colonia, Germania, riguardante l'ingegneria inversa non autorizzata degli anticorpi proprietari NKG2C/CD159c di Bio-Techne. Il tribunale ha stabilito che gli anticorpi di Miltenyi avevano regioni variabili identiche al 100% ai prodotti a marchio R&D Systems di Bio-Techne.
Questa vittoria segue un caso simile del 2023 in cui è stato riscontrato che Miltenyi aveva effettuato ingegneria inversa sugli anticorpi TIGIT e CCR-7 di Bio-Techne. Il tribunale ha assegnato a Bio-Techne un risarcimento monetario per le vendite degli anticorpi ingegnerizzati, il rimborso delle spese per dimostrare la copia e il diritto a ulteriori informazioni sulle attività illegali di Miltenyi. Miltenyi conserva il diritto di appellarsi alla sentenza.
Bio-Techne (NASDAQ: TECH) ha ganado otro caso legal contra Miltenyi Biotec en el Tribunal Regional de Colonia, Alemania, relacionado con la ingeniería inversa no autorizada de los anticuerpos NKG2C/CD159c de Bio-Techne. El tribunal determinó que los anticuerpos de Miltenyi tenían regiones variables idénticas al 100% con los productos de Bio-Techne bajo la marca R&D Systems.
Esta victoria sigue un caso similar de 2023 donde se encontró que Miltenyi había realizado ingeniería inversa de los anticuerpos TIGIT y CCR-7 de Bio-Techne. El tribunal ha otorgado a Bio-Techne daños económicos por las ventas de los anticuerpos cuya ingeniería fue revertida, el reembolso de los costos para demostrar la copia y derechos a información adicional sobre las actividades ilícitas de Miltenyi. Miltenyi mantiene el derecho a apelar el fallo.
Bio-Techne (NASDAQ: TECH)는 독일 쾰른 지방 법원에서 Miltenyi Biotec를 상대로 한 또 다른 법적 사건에서 승소했습니다. 이 사건은 Bio-Techne의 독점적인 NKG2C/CD159c 항체의 무단 역설계에 관한 것입니다. 법원은 Miltenyi의 항체가 Bio-Techne의 R&D Systems 브랜드 제품의 변동 영역과 100% 동일하다고 판단했습니다.
이번 승리는 2023년 Miltenyi가 Bio-Techne의 TIGIT 및 CCR-7 항체를 역설계한 것으로 판단된 유사한 사건에 이어 발생했습니다. 법원은 Bio-Techne에게 역설계된 항체의 판매로 인한 금전적 손해배상, 복제를 입증하기 위한 비용 상환 및 Miltenyi의 불법 활동에 대한 추가 정보에 대한 권리를 부여했습니다. Miltenyi는 판결에 대한 항소권을 유지합니다.
Bio-Techne (NASDAQ: TECH) a remporté un autre procès contre Miltenyi Biotec devant le tribunal régional de Cologne, en Allemagne, concernant l'ingénierie inversée non autorisée des anticorps NKG2C/CD159c de Bio-Techne. Le tribunal a constaté que les anticorps de Miltenyi présentaient des régions variables identiques à 100 % à celles des produits de Bio-Techne sous la marque R&D Systems.
Cette victoire fait suite à un cas similaire en 2023, où Miltenyi a été reconnu coupable d'avoir procédé à l'ingénierie inversée des anticorps TIGIT et CCR-7 de Bio-Techne. Le tribunal a accordé à Bio-Techne des dommages-intérêts financiers pour les ventes des anticorps issus de l'ingénierie inversée, le remboursement des frais pour la démonstration de la contrefaçon et des droits à des informations supplémentaires sur les activités illégales de Miltenyi. Miltenyi se réserve le droit de faire appel de la décision.
Bio-Techne (NASDAQ: TECH) hat einen weiteren Rechtsstreit gegen Miltenyi Biotec vor dem Kölner Landgericht gewonnen, der die unbefugte Rückentwicklung der proprietären NKG2C/CD159c-Antikörper von Bio-Techne betrifft. Das Gericht stellte fest, dass die Antikörper von Miltenyi zu 100 % identische variable Regionen wie die Produkte von Bio-Techne unter der Marke R&D Systems aufwiesen.
Dieser Sieg folgt einem ähnlichen Fall aus dem Jahr 2023, in dem Miltenyi aufgrund unbefugter Rückentwicklung der TIGIT- und CCR-7-Antikörper von Bio-Techne verurteilt wurde. Das Gericht hat Bio-Techne finanzielle Schäden für den Verkauf der rückentwickelten Antikörper, eine Erstattung der Kosten für den Nachweis der Nachahmung sowie Rechte auf zusätzliche Informationen über die illegalen Aktivitäten von Miltenyi zugesprochen. Miltenyi behält sich das Recht vor, gegen das Urteil Berufung einzulegen.
- Court victory grants Bio-Techne monetary damages for unauthorized antibody sales
- Court awards reimbursement of costs for proving intellectual property infringement
- Company gains right to detailed information about Miltenyi's reverse engineering activities
- Potential appeal by Miltenyi could extend legal proceedings
- Ongoing intellectual property violations indicate continued market competition risks
Insights
The Cologne Regional Court's ruling represents a significant legal victory for Bio-Techne in protecting its intellectual property rights. The court's finding of 100% identical variable regions in antibodies is particularly compelling evidence of reverse engineering. The ruling's scope is comprehensive, covering both injunctive relief and monetary damages, including unusual provisions for cost reimbursement related to proving the copying.
This second successful case against Miltenyi establishes a strong legal precedent and pattern of behavior, strengthening Bio-Techne's position in any future IP disputes. The damages award, while not yet quantified, could be substantial given the specialized nature of these antibodies in the research market. The possibility of appeal by Miltenyi adds uncertainty, but the clear evidence of identical variable regions makes the ruling likely to withstand appellate review.
This ruling has broader implications for the $70+ billion research antibody market. The court's decision protects Bio-Techne's R&D Systems brand, which is important in the high-margin antibody business where proprietary products command premium prices. The pattern of reverse engineering by Miltenyi suggests potential market share erosion that's now been legally addressed.
For investors, this represents enhanced protection of Bio-Techne's intellectual property portfolio and future revenue streams. The antibody business typically carries 70-80% gross margins, making IP protection vital for maintaining profitability. In simpler terms, it's like catching someone copying your secret recipe - not only do they have to stop, but they also have to pay you for what they've already sold using your recipe.
Bio-Techne took legal action against Miltenyi in the
"We are pleased the court has recognized that Miltenyi has repeatedly and unlawfully passed off Bio-Techne's proprietary innovations to Miltenyi's customers as their own," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We have spent almost five decades developing our extensive catalogue of solutions that enable the scientific community to discover novel biological insights and develop advanced therapeutics. We will continue to vigorously defend our intellectual property against Miltenyi and any other potential offenders."
Miltenyi may appeal the Court's ruling.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-successful-on-second-claim-of-reverse-engineering-by-miltenyi-biotec-302343926.html
SOURCE Bio-Techne Corporation
FAQ
What was the outcome of Bio-Techne's (TECH) latest legal case against Miltenyi Biotec?
How many legal victories has Bio-Techne (TECH) secured against Miltenyi for reverse engineering?
What compensation will Bio-Techne (TECH) receive from the 2025 Miltenyi court ruling?
Which Bio-Techne (TECH) antibodies did Miltenyi Biotec illegally reverse engineer in the 2025 case?
